Correlation Between Acrivon Therapeutics, and Tempest Therapeutics

Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Tempest Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Tempest Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Acrivon Therapeutics, Common and Tempest Therapeutics, you can compare the effects of market volatilities on Acrivon Therapeutics, and Tempest Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Tempest Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Tempest Therapeutics.

Diversification Opportunities for Acrivon Therapeutics, and Tempest Therapeutics

0.16

Correlation Coefficient

Acrivon Therapeutics,  Tempest Therapeutics

Average diversification

The 3 months correlation between Acrivon and Tempest is 0.16. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Tempest Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Tempest Therapeutics and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Tempest Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Tempest Therapeutics has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Tempest Therapeutics go up and down completely randomly.

Pair Corralation between Acrivon Therapeutics, and Tempest Therapeutics

Given the investment horizon of 90 days Acrivon Therapeutics, Common is expected to generate 0.79 times more return on investment than Tempest Therapeutics. However, Acrivon Therapeutics, Common is 1.26 times less risky than Tempest Therapeutics. It trades about -0.01 of its potential returns per unit of risk. Tempest Therapeutics is currently generating about -0.17 per unit of risk. If you would invest  717.00  in Acrivon Therapeutics, Common on September 25, 2024 and sell it today you would lose (46.00) from holding Acrivon Therapeutics, Common or give up 6.42% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Acrivon Therapeutics, Common  vs.  Tempest Therapeutics

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Acrivon Therapeutics, is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Tempest Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Tempest Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Acrivon Therapeutics, and Tempest Therapeutics

The main advantage of trading using opposite Acrivon Therapeutics, and Tempest Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Tempest Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tempest Therapeutics will offset losses from the drop in Tempest Therapeutics' long position.

The idea behind Acrivon Therapeutics, Common and Tempest Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.